PMID- 20666708
OWN - NLM
STAT- MEDLINE
DCOM- 20100929
LR  - 20211028
IS  - 1040-8401 (Print)
IS  - 1040-8401 (Linking)
VI  - 30
IP  - 4
DP  - 2010
TI  - The role of chemokines in migration of metastatic-like lymphangioleiomyomatosis 
      cells.
PG  - 387-94
AB  - Lymphangioleiomyomatosis (LAM), a rare cystic lung disease with multi-organ 
      involvement, occurs primarily in women of childbearing age. LAM can present 
      sporadically or in association with tuberous sclerosis complex (TSC). Loss of 
      lung function in patients with LAM can be attributed to the dysregulated growth 
      of LAM cells, with dysfunctional TSC1 or TSC2 genes, which encode hamartin and 
      tuberin, respectively, leading to hyperactivation of the mammalian target of 
      rapamycin (mTOR). LAM cells are smooth muscle-like cells that express melanoma 
      antigens such as gp100, a splice variant of the Pmel17 gene. Tuberin and hamartin 
      form heterodimers that act as negative regulators of mTOR. Lack of TSC2 function, 
      as occurs in LAM cells, leads to the production of the chemokine CCL2/monocyte 
      chemotactic protein 1 (MCP-1), which increases LAM cell mobility. Although many 
      chemokines and their receptors could influence LAM cell mobilization, we propose 
      that a positive-feedback loop is generated when dysfunctional TSC2 is present in 
      LAM cells. We identified a group of chemokine receptors that is expressed in LAM 
      cells and differs from those on smooth muscle and melanoma cells (Malme-3M). 
      Chemokines have been implicated in tumor metastasis, and our data suggest a role 
      for chemokines in LAM cell mobilization and thereby in the pathogenesis of LAM.
FAU - Pacheco-Rodriguez, Gustavo
AU  - Pacheco-Rodriguez G
AD  - Translational Medicine Branch, National Heart, Lung, and Blood Institute, 
      National Institutes of Health, Bethesda, MD 20892-1590, USA.
FAU - Moss, Joel
AU  - Moss J
LA  - eng
GR  - Z01 HL002541-12/ImNIH/Intramural NIH HHS/United States
GR  - Z01 HL002541-13/ImNIH/Intramural NIH HHS/United States
GR  - ZIA HL002541-14/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Crit Rev Immunol
JT  - Critical reviews in immunology
JID - 8914819
RN  - 0 (Chemokines)
RN  - 0 (Receptors, Chemokine)
SB  - IM
MH  - Animals
MH  - *Cell Movement
MH  - Chemokines/*immunology
MH  - Humans
MH  - Lung Neoplasms/immunology/pathology
MH  - Lymphangioleiomyomatosis/*immunology/pathology
MH  - Neoplasm Metastasis/immunology
MH  - Receptors, Chemokine/immunology
PMC - PMC3021991
MID - NIHMS232665
EDAT- 2010/07/30 06:00
MHDA- 2010/09/30 06:00
PMCR- 2011/01/17
CRDT- 2010/07/30 06:00
PHST- 2010/07/30 06:00 [entrez]
PHST- 2010/07/30 06:00 [pubmed]
PHST- 2010/09/30 06:00 [medline]
PHST- 2011/01/17 00:00 [pmc-release]
AID - 2a2a299c5ed1858d,4cfb74b563cc4363 [pii]
AID - 10.1615/critrevimmunol.v30.i4.40 [doi]
PST - ppublish
SO  - Crit Rev Immunol. 2010;30(4):387-94. doi: 10.1615/critrevimmunol.v30.i4.40.